Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL_Matthew Davids, MD, MMSc
41:32
Chronic Lymphocytic Leukemia
Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL_Matthew Davids, MD, MMSc
Chronic Lymphocytic Leukemia Similar Videos
Similar Videos
-
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59
-
Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE
8:16